Cuticular drusen: Stars in the sky

Progress in Retinal and Eye Research

Volumn 37, Issue , 2013, Pages 90-113

  Boon, Camiel J F ^a,b,c   van de Ven, Johannes P H ^a   Hoyng, Carel B ^a   den Hollander, Anneke I ^a   Klevering, B Jeroen ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age related macular degeneration; Complement system; Cuticular drusen; Drusen; Genetics

Indexed keywords

COMPLEMENT FACTOR I; FIBULIN 5;

ALPORT SYNDROME; CHROMOSOME 6Q; COMPLEMENT ACTIVATION; DIFFERENTIAL DIAGNOSIS; DRUSEN; ELECTROPHYSIOLOGY; EYE FUNDUS ALBIPUNCTATUS; FLUORESCENCE ANGIOGRAPHY; GENE MAPPING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; MALATTIA LEVENTINESE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MICROPERIMETRY; NORTH CAROLINA MACULAR DYSTROPHY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PSEUDOXANTHOMA ELASTICUM; RETINA DYSTROPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINITIS; REVIEW; STARGARDT DISEASE; VISUAL SYSTEM EXAMINATION;

AGE-RELATED MACULAR DEGENERATION; COMPLEMENT SYSTEM; CUTICULAR DRUSEN; DRUSEN; GENETICS;

COMPLEMENT SYSTEM PROTEINS; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MACULAR DEGENERATION; PIGMENT EPITHELIUM OF EYE; RETINAL DRUSEN; RISK FACTORS;

EID: 84887363298     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.08.003     Document Type: Review

References (241)

1. Abrera-Abeleda M.A., et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J.Med. Genet. 2006, 43:582-589.
2. Agbeko R.S., et al. Genetic variability in complement activation modulates the systemic inflammatory response syndrome in children. Pediatr. Crit. Care Med. A J. Soc. Crit. Care Med. World Fed. Pediatr. Intensive Crit. Care Societies 2010, 11:561-567.
3. Al-Hussaini H., et al. Drusen are associated with local and distant disruptions to human retinal pigment epithelium cells. Exp. Eye. Res. 2009, 88:610-612.
4. Albig A.R., Schiemann W.P. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA. Cell. Biol. 2004, 23:367-379.
5. Alchi B., Jayne D. Membranoproliferative glomerulonephritis. Pediatr. Nephrol. 2010, 25:1409-1418.
6. Anderson D.H., et al. Arole for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 2002, 134:411-431.
7. Anderson D.H., et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am. J. Ophthalmol. 2001, 131:767-781.
8. Anderson D.H., et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye. Res. 2010, 29:95-112.
9. Anderson D.H., et al. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp. Eye. Res. 2004, 78:243-256.
10. Appel G.B., et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J.Am. Soc. Nephrol. 2005, 16:1392-1403.
11. Awan M.A., et al. Bilateral macular sub-retinal fluid and retinal pigment epithelial detachment associated with type 2 membrano-proliferative glomerulonephritis. Clin. Exp. Opt. J. Aust. Optometric. Assoc. 2008, 91:476-479.
12. Ball R.Y., et al. Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis 1995, 114:45-54.
13. Barbazetto I.A., et al. Pseudo-vitelliform macular detachment and cuticular drusen: exclusion of 6 candidate genes. Ophthalmic. Genet. 2007, 28:192-197.
14. Beattie J.R., et al. Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. FASEB J. 2010, 24:4816-4824.
15. Bergen A.A., et al. Mutations in ABCC6 cause Pseudoxanthoma elasticum. Nat. Genet. 2000, 25:228-231.
16. Berger S.P., Daha M.R. Complement in glomerular injury. Semin. Immunopathol. 2007, 29:375-384.
17. Bienaime F., et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney. Int. 2010, 77:339-349.
18. Bird A.C., et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalmol. 1995, 39:367-374.
19. Bok D. The retinal pigment epithelium: a versatile partner in vision. J.Cell. Sci. 1993, 189-195. Suppl.17.
20. Booij J.C., et al. The dynamic nature of Bruch's membrane. Prog. Retin. Eye. Res. 2010, 29:1-18.
21. Boon C.J.F., et al. The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS gene. Prog. Retin. Eye. Res. 2008, 27:213-235.
22. Boon C.J.F., et al. Basal laminar drusen caused by compound heterozygous variants in the CFH gene. Am. J. Hum. Genet. 2008, 82:516-523.
23. Boon C.J.F., et al. Central areolar choroidal dystrophy. Ophthalmology 2009, 116:771-782. 782e771.
24. Boon C.J.F., et al. The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog. Retin. Eye. Res. 2009, 28:187-205.
25. Boon C.J.F., et al. Clinical and molecular genetic analysis of best vitelliform macular dystrophy. Retina 2009, 29:835-847.
26. Boon C.J.F., et al. The spectrum of phenotypes caused by variants in the CFH gene. Mol. Immunol. 2009, 46:1573-1594.
27. Boon C.J.F., et al. Mutations in the peripherin/RDS gene are an important cause of multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus. Br. J. Ophthalmol. 2007, 91:1504-1511.
28. Boudreault G., et al. [Canthaxanthine retinopathy: 1. Clinical study in 51 consumers]. Can. J. Ophthalmol. Journal canadien d'ophtalmologie 1983, 18:325-328.
29. Bresin E., et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J.Am. Soc. Nephrol. 2013, 24:475-486.
30. Bressler N.M., et al. Age-related macular degeneration. Surv. Ophthalmol. 1988, 32:375-413.
31. Callewaert B., et al. Comprehensive clinical and molecular analysis of 12 families with type 1 recessive cutis laxa. Hum. Mutat. 2013, 34:111-121.
32. Cameron J.S., et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am. J. Med. 1983, 74:175-192.
33. Caprioli J., et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J. Am. Soc. Nephrol. 2001, 12:297-307.
34. Caprioli J., et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 2003, 12:3385-3395.
35. Chen W., et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc. Natl. Acad. Sci. U S A 2010, 107:7401-7406.
36. Cohen S.Y., et al. Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularisation. Br. J. Ophthalmol. 2007, 91:354-359.
37. Cohen S.Y., et al. Visual function and course of basal laminar drusen combined with vitelliform macular detachment. Br. J. Ophthalmol. 1994, 78:437-440.
38. Colville D., et al. Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II ("dense deposit disease"). Am. J. Kidney Dis. Off. J. Nat. Kidney Found. 2003, 42:E2-E5.
39. Crabb J.W., et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. U S A 2002, 99:14682-14687.
40. Curcio C.A., et al. Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog. Retin. Eye. Res. 2009, 28:393-422.
41. Curcio C.A., et al. The oil spill in ageing Bruch membrane. Br. J. Ophthalmol. 2011, 95:1638-1645.
42. Curcio C.A., et al. Subretinal drusenoid deposits in non-neovascular age-related macular degeneration: morphology, prevalence, topography, and biogenesis model. Retina 2013, 33:265-276.
43. D'Souza Y.B., et al. Basal laminar drusen and soft drusen have similar glycan composition. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2010, 45:297-299.
44. D'Souza Y., et al. Long-term follow-up of drusen-like lesions in patients with type II mesangiocapillary glomerulonephritis. Br. J. Ophthalmol. 2008, 92:950-953.
45. Daha M.R., van Es L.A. Further evidence for the antibody nature of C3 nephritic factor (C3NeF). J.Immunol. 1979, 123:755-758.
46. Dasari B., et al. The oxysterol 27-hydroxycholesterol increases beta-amyloid and oxidative stress in retinal pigment epithelial cells. BMC. Ophthalmol. 2010, 10:22.
47. de Jong P.T. Age-related macular degeneration. N.Engl. J. Med. 2006, 355:1474-1485.
48. de Laat P. Mitochondrial retinal dystrophy associated with the m.3243A>G mutation. Ophthalmology 2013, [published online ahead of print]. 10.1016/j.ophtha.2013.05.013.
49. Deutman A.F. Electro-oculography in families with vitelliform dystrophy of the fovea. Detection of the carrier state. Arch. Ophthalmol. 1969, 81:305-316.
50. Dolz-Marco R., et al. [New macular tomography findings in Alport syndrome]. Archivos de la Sociedad Espanola de Oftalmologia 2012, 87:55-56.
51. Donders F.C. Beiträge zur pathologischen anatomie des auges. Graefes. Arch. Clin. Exp. Ophthalmol. 1855, 2:106-118.
52. Duvall-Young J., et al. Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br. J. Ophthalmol. 1989, 73:297-302.
53. Duvall-Young J., et al. Fundus changes in mesangiocapillary glomerulonephritis type II: clinical and fluorescein angiographic findings. Br. J. Ophthalmol. 1989, 73:900-906.
54. Edwards A.O., et al. Malattia leventinese: refinement of the genetic locus and phenotypic variability in autosomal dominant macular drusen. Am. J. Ophthalmol. 1998, 126:417-424.
55. Edwards A.O., et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
56. Elahi E., et al. Homozygous missense mutation in fibulin-5 in an Iranian autosomal recessive cutis laxa pedigree and associated haplotype. J.Invest. Dermatol. 2006, 126:1506-1509.
57. Ergun E., et al. Photodynamic therapy and vitelliform lesions. Retina 2004, 24:399-406.
58. Evans K., et al. Assessment of the phenotypic range seen in Doyne honeycomb retinal dystrophy. Arch. Ophthalmol. 1997, 115:904-910.
59. Fagerness J.A., et al. Variation near complement factor I is associated with risk of advanced AMD. Eur. J. Hum. Genet. 2009, 17:100-104.
60. Fakhouri F., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J.Am. Soc. Nephrol. 2010, 21:859-867.
61. Farah S.E., et al. Treatment of subretinal neovascular membrane in a patient with membranoproliferative glomerulonephritis type II. Ophthalmic Surg Lasers Imaging 2009, 40:416-418.
62. Ferreira V.P., et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J.Immunol. 2009, 182:7009-7018.
63. Finger R.P., et al. Spectral domain optical coherence tomography in adult-onset vitelliform macular dystrophy with cuticular drusen. Retina 2010, 30:1455-1464.
64. Finger R.P., et al. Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv. Ophthalmol. 2009, 54:272-285.
65. Fishman G.A., et al. The electro-oculogram in diffuse (familial) drusen. Arch. Ophthalmol. 1976, 94:231-233.
66. Fleckenstein M., et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2008, 49:4137-4144.
67. Fleckenstein M., et al. Fundus autofluorescence and spectral-domain optical coherence tomography characteristics in a rapidly progressing form of geographic atrophy. Invest. Ophthalmol. Vis. Sci. 2011, 52:3761-3766.
68. Fornaro P., et al. Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis. Documenta ophthalmologica. Adv. Ophthalmol. 2002, 105:41-49.
69. Freund K.B., et al. Acquired vitelliform lesions: correlation of clinical findings and multiple imaging analyses. Retina 2011, 31:13-25.
70. Friedman D.S., et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122:564-572.
71. Gass J.D.M. Stereoscopic Atlas of Macular Disease: Diagnosis and Treatment 1977, Mosby, St. Louis, MO. fifth ed.
72. Gass J.D.M., et al. Adult vitelliform macular detachment occurring in patients with basal laminar drusen. Am. J. Ophthalmol. 1985, 99:445-459.
73. Gehrs K.M., et al. Clinical features and pathogenesis of Alport retinopathy. Retina 1995, 15:305-311.
74. Genead M.A., et al. Spectral-domain optical coherence tomography and fundus autofluorescence characteristics in patients with fundus albipunctatus and retinitis punctata albescens. Ophthalmic. Genet. 2010, 31:66-72.
75. Gold B., et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 2006, 38:458-462.
76. Gomi F., et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008, 115:141-146.
77. Goto Y., et al. Amutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990, 348:651-653.
78. Grassi M.A., et al. Complement factor H polymorphism p.Tyr402His and cuticular Drusen. Arch. Ophthalmol. 2007, 125:93-97.
79. Guigui B., et al. Angiography features of early onset drusen. Br. J. Ophthalmol. 2011, 95:238-244.
80. Guigui B., et al. Photodynamic therapy for choroidal neovascularisation secondary to basal laminar drusen. Eye (Lond.) 2009, 23:2115-2118.
81. Guigui B., et al. Spectral-domain optical coherence tomography of early onset large colloid drusen. Retina 2013, 33:1346-1350.
82. Hageman G.S., et al. Acommon haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U S A 2005, 102:7227-7232.
83. Hageman G.S., et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye. Res. 2001, 20:705-732.
84. Haimovici R., et al. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 2002, 109:164-171.
85. Haines J.L., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
86. Hamel C.P., et al. Extensive macular atrophy with pseudodrusen-like appearance: a new clinical entity. Am. J. Ophthalmol. 2009, 147:609-620.
87. Hassenstein A., Richard G. Choroidal neovascularisation in type II membranoproliferative glomerulonephritis, photodynamic therapy as a treatment option - a case report. Klin Monbl Augenheilkd 2003, 220:492-495.
88. Herbert A.P., et al. Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism. J.Biol. Chem. 2007, 282:18960-18968.
89. Hogg R.E., et al. Genotype-phenotype associations in neovascular age-related macular degeneration. Retina 2012, 32:1950-1958.
90. Holz F.G., et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am. J. Ophthalmol. 2007, 143:463-472.
91. Hoskin A., et al. Sorsby's pseudoinflammatory macular dystrophy. Br. J. Ophthalmol. 1981, 65:859-865.
92. Huang J.D., et al. Age-related changes in human macular Bruch's membrane as seen by quick-freeze/deep-etch. Exp. Eye. Res. 2007, 85:202-218.
93. Huang S.J., et al. Peripheral drusen in membranoproliferative glomerulonephritis type II. Retina 2003, 23:429-431.
94. Inatani M., Tanihara H. Proteoglycans in retina. Prog. Retin. Eye. Res. 2002, 21:429-447.
95. Jakobsdottir J., et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am. J. Hum. Genet. 2005, 77:389-407.
96. Johnson L.V., et al. Apotential role for immune complex pathogenesis in drusen formation. Exp. Eye. Res. 2000, 70:441-449.
97. Johnson P.T., et al. Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest. Ophthalmol. Vis. Sci. 2005, 46:4788-4795.
98. Johnson P.T., et al. Drusen-associated degeneration in the retina. Invest. Ophthalmol. Vis. Sci. 2003, 44:4481-4488.
99. Jones R.P., et al. Structural effects of fibulin 5 missense mutations associated with age-related macular degeneration and cutis laxa. Invest. Ophthalmol. Vis. Sci. 2010, 51:2356-2362.
100. Kaemmerer E., et al. Effects of lipid peroxidation-related protein modifications on RPE lysosomal functions and POS phagocytosis. Invest. Ophthalmol. Vis. Sci. 2007, 48:1342-1347.
101. Karampelas M., et al. Patient with type II membranoproliferative glomerulonephritis: Intravitreal bevacizumab therapy for choroidal neovascularization. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2012, 109:791-793.
102. Kawasaki R., et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010, 117:921-927.
103. Khanifar A.A., et al. Drusen ultrastructure imaging with spectral domain optical coherence tomography in age-related macular degeneration. Ophthalmology 2008, 115:1883-1890.
104. Kiernan D.F., et al. Thirty-Year follow-up of an African American family with macular dystrophy of the retina, locus 1 (North Carolina macular dystrophy). Ophthalmology 2011, 118:1435-1443.
105. Kim Y., et al. Immunofluorescence studies of dense deposit disease. The presence of railroad tracks and mesangial rings. Lab. Invest. 1979, 40:474-480.
106. Klein M.L., et al. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 2008, 115:1026-1031.
107. Klein R., et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007, 114:253-262.
108. Klein R.J., et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
109. Klevering B.J., et al. The spectrum of retinal phenotypes caused by mutations in the ABCA4 gene. Graefes. Arch. Clin. Exp. Ophthalmol. 2005, 243:90-100.
110. Klevering B.J., et al. Central areolar choroidal dystrophy associated with dominantly inherited drusen. Br. J. Ophthalmol. 2002, 86:91-96.
111. Kniazeva M., et al. Anew locus for dominant drusen and macular degeneration maps to chromosome 6q14. Am. J. Ophthalmol. 2000, 130:197-202.
112. Krishnan T., et al. Prevalence of early and late age-related macular degeneration in India: the INDEYE study. Invest. Ophthalmol. Vis. Sci. 2010, 51:701-707.
113. Lai T.Y., et al. Genotype phenotype analysis of Bietti's crystalline dystrophy in patients with CYP4V2 mutations. Invest. Ophthalmol. Vis. Sci. 2007, 48:5212-5220.
114. Laine M., et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J.Immunol. 2007, 178:3831-3836.
115. Leng T., et al. Spectral domain optical coherence tomography characteristics of cuticular drusen. Retina 2009, 29:988-993.
116. Lengyel I., et al. High concentration of zinc in sub-retinal pigment epithelial deposits. Exp. Eye. Res. 2007, 84:772-780.
117. Lerche W. Pigment Epithelium Changes in Drusen of the Macular Region 1975, 439-446. Bericht uber die Zusammenkunft, Deutsche Ophthalmologische Gesellschaft.
118. Leys A., et al. Specific eye fundus lesions in type II membranoproliferative glomerulonephritis. Pediatr. Nephrol. 1991, 5:189-192.
119. Leys A., et al. Sequential observation of fundus changes in patients with long standing membranoproliferative glomerulonephritis type II (MPGN type II). Eur. J. Ophthalmol. 1991, 1:17-22.
120. Leys A., et al. Fundus changes in membranoproliferative glomerulonephritis type II. A fluorescein angiographic study of 23 patients. Graefes. Arch. Clin. Exp. Ophthalmol. 1991, 229:406-410.
121. Licht C., et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney. Int. 2006, 70:42-50.
122. Lin R.J., et al. Anovel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. Am. J. Ophthalmol. 2006, 142:839-848.
123. Loeys B., et al. Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. Hum. Mol. Genet. 2002, 11:2113-2118.
124. Lotery A.J., et al. Reduced secretion of fibulin 5 in age-related macular degeneration and cutis laxa. Hum. Mutat. 2006, 27:568-574.
125. Maga T.K., et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum. Mutat. 2010, 31:E1445-E1460.
126. Malek G., et al. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am. J. Pathol. 2003, 162:413-425.
127. Manuelian T., et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J.Clin. Invest. 2003, 111:1181-1190.
128. Marshall G.E., et al. Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula. Br. J. Ophthalmol. 1992, 76:607-614.
129. Martinez-Barricarte R., et al. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J.Am. Soc. Nephrol. 2008, 19:639-646.
130. Massin P., et al. Prevalence of macular pattern dystrophy in maternally inherited diabetes and deafness. GEDIAM Group. Ophthalmology 1999, 106:1821-1827.
131. Maugeri A., et al. Anovel mutation in the ELOVL4 gene causes autosomal dominant Stargardt-like macular dystrophy. Invest. Ophthalmol. Vis. Sci. 2004, 45:4263-4267.
132. McAvoy C.E., Silvestri G. Retinal changes associated with type 2 glomerulonephritis. Eye (Lond.) 2005, 19:985-989.
133. Meunier I., et al. Five-year evolution of basal laminar drusen combined with vitelliform macular detachment. Arch. Ophthalmol. 2004, 122:1566-1567.
134. Meyerle C.B., et al. Autofluorescence of basal laminar drusen. Retina 2007, 27:1101-1106.
135. Michaelides M., et al. Macular dystrophy associated with the A3243G mitochondrial DNA mutation. Distinct retinal and associated features, disease variability, and characterization of asymptomatic family members. Arch. Ophthalmol. 2008, 126:320-328.
136. Michaelides M., et al. Maculopathy due to the R345W substitution in fibulin-3: distinct clinical features, disease variability, and extent of retinal dysfunction. Invest. Ophthalmol. Vis. Sci. 2006, 47:3085-3097.
137. Michaelides M., et al. An early-onset autosomal dominant macular dystrophy (MCDR3) resembling North Carolina macular dystrophy maps to chromosome 5. Invest. Ophthalmol. Vis. Sci. 2003, 44:2178-2183.
138. Midena E., et al. Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration. Br. J. Ophthalmol. 2007, 91:1499-1503.
139. Mimoun G., et al. Macular drusen. J.francais d'ophtalmologie 1990, 13:511-530.
140. Montes T., et al. Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. Mol. Immunol. 2008, 45:2897-2904.
141. Montes T., et al. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc. Natl. Acad. Sci. U S A 2009, 106:4366-4371.
142. Moreira E.F., et al. 7-Ketocholesterol is present in lipid deposits in the primate retina: potential implication in the induction of VEGF and CNV formation. Invest. Ophthalmol. Vis. Sci. 2009, 50:523-532.
143. Mueller E.E., et al. Mitochondrial haplogroups and control region polymorphisms in age-related macular degeneration: a case-control study. PLoS One 2012, 7:e30874.
144. Müller H. Anatomische beiträge zur ophthalmologie. Albrecht von Graefes Arch. Ophthalmol. 1856, 2:1-69.
145. Mullins R.F. Genetic insights into the pathobiology of age-related macular degeneration. Int. Ophthalmol. Clin. 2007, 47:1-14.
146. Mullins R.F., Hageman G.S. Human ocular drusen possess novel core domains with a distinct carbohydrate composition. J.Histochem. Cytochem. 1999, 47:1533-1540.
147. Mullins R.F., et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000, 14:835-846.
148. Neale B.M., et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). Proc. Natl. Acad. Sci. U S A 2010, 107:7395-7400.
149. Neumann H.P., et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J.Med. Genet. 2003, 40:676-681.
150. Newsome D.A., et al. Bruch's membrane age-related changes vary by region. Curr. Eye. Res. 1987, 6:1211-1221.
151. Nguyen A.D., et al. Fibulin-5 is a novel binding protein for extracellular superoxide dismutase. Circ. Res. 2004, 95:1067-1074.
152. Ormsby R.J., et al. Functional and structural implications of the complement factor H Y402H polymorphism associated with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2008, 49:1763-1770.
153. Orth S.R., Ritz E. The nephrotic syndrome. N.Engl. J. Med. 1998, 338:1202-1211.
154. Pauleikhoff D., et al. Aging changes in Bruch's membrane. A histochemical and morphologic study. Ophthalmology 1990, 97:171-178.
155. Pauleikhoff D., et al. Correlation between biochemical composition and fluorescein binding of deposits in Bruch's membrane. Ophthalmology 1992, 99:1548-1553.
156. Perez-Caballero D., et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2001, 68:478-484.
157. Pilli S., et al. High-resolution Fourier-domain optical coherence tomography findings in vitelliform detachment associated with basal laminar drusen. Retina 2011, 31:812-814.
158. Priya R.R., et al. Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management. Ophthalmology 2012, 119:2526-2536.
159. Querques G., et al. Multimodal morphological and functional characterization of Malattia Leventinese. Graefes. Arch. Clin. Exp. Ophthalmol. 2013, 251:705-714.
160. Querques G., et al. Insights into pathology of cuticular drusen from integrated confocal scanning laser ophthalmoscopy imaging and corresponding spectral domain optical coherence tomography. Graefes. Arch. Clin. Exp. Ophthalmol. 2011, 249:1617-1625.
161. Querques G., et al. In-vivo visualization of retinal crystals in Bietti's crystalline dystrophy by spectral domain optical coherence tomography. Ophthalmic. Surg. Lasers Imag. 2010, 1-3.
162. Rath P.P., et al. Characterisation of the macular dystrophy in patients with the A3243G mitochondrial DNA point mutation with fundus autofluorescence. Br. J. Ophthalmol. 2008, 92:623-629.
163. Raychaudhuri S., et al. Arare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat. Genet. 2011, 43:1232-1236.
164. Rein D.B., et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch. Ophthalmol. 2009, 127:533-540.
165. Reynolds R., et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest. Ophthalmol. Vis. Sci. 2009, 50:5818-5827.
166. Rivera A., et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum. Mol. Genet. 2005, 14:3227-3236.
167. Rosenberg T., et al. Clinical and genetic characterization of a Danish family with North Carolina macular dystrophy. Mol. Vis. 2010, 16:2659-2668.
168. Ruberti J.W., et al. Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch's membrane. Invest. Ophthalmol. Vis. Sci. 2003, 44:1753-1759.
169. Rudolf M., et al. Prevalence and morphology of druse types in the macula and periphery of eyes with age-related maculopathy. Invest. Ophthalmol. Vis. Sci. 2008, 49:1200-1209.
170. Russell S.R., et al. Comparison of color to fluorescein angiographic images from patients with early-adult onset grouped drusen suggests drusen substructure. Am. J. Ophthalmol. 2004, 137:924-930.
171. Russell S.R., et al. Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration. Am. J. Ophthalmol. 2000, 129:205-214.
172. Saihan Z., et al. Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy. Mol. Vis. 2009, 15:1218-1230.
173. Sanchez-Corral P., et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2002, 71:1285-1295.
174. Sarks J., et al. Evolution of reticular pseudodrusen. Br. J. Ophthalmol. 2011, 95:979-985.
175. Sarks J.P., et al. Evolution of soft drusen in age-related macular degeneration. Eye (Lond.) 1994, 8(Pt 3):269-283.
176. Sarks S.H. Ageing and degeneration in the macular region: a clinico-pathological study. Br. J. Ophthalmol. 1976, 60:324-341.
177. Sarks S.H., et al. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. Br. J. Ophthalmol. 1999, 83:358-368.
178. Schneider R., et al. Biophysical characterisation of fibulin-5 proteins associated with disease. J.Mol. Biol. 2010, 401:605-617.
179. Scholl H.P., et al. Photopic and scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy. Invest. Ophthalmol. Vis. Sci. 2004, 45:574-583.
180. Scholl H.P., et al. Systemic complement activation in age-related macular degeneration. PLoS One 2008, 3:e2593.
181. Schultz D.W., et al. Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. Hum. Mol. Genet. 2003, 12:3315-3323.
182. Schwertz R., et al. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr. Allergy. Immunol. 2001, 12:166-172.
183. Seddon J.M., et al. Familial aggregation of age-related maculopathy. Am. J. Ophthalmol. 1997, 123:199-206.
184. Seddon J.M., et al. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch. Ophthalmol. 2005, 123:321-327.
185. Seddon J.M., et al. Peripheral retinal drusen and reticular pigment: association with CFHY402H and CFHrs1410996 genotypes in family and twin studies. Invest. Ophthalmol. Vis. Sci. 2009, 50:586-591.
186. Seddon J.M., et al. Evaluation of the clinical age-related maculopathy staging system. Ophthalmology 2006, 113:260-266.
187. Sergouniotis P.I., et al. Retinal structure, function, and molecular pathologic features in gyrate atrophy. Ophthalmology 2012, 119:596-605.
188. Servais A., et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J. Med. Genet. 2007, 44:193-199.
189. Servais A., et al. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum. Pathol. 2011, 42:1305-1311.
190. Shaw P.X., et al. Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc. Natl. Acad. Sci. U S A 2012, 109:13757-13762.
191. Shuler R.K., et al. Phenotype analysis of patients with the risk variant LOC387715 (A69S) in age-related macular degeneration. Am. J. Ophthalmol. 2008, 145:303-307.
192. Sivaprasad S., et al. Clinical course and treatment outcomes of Sorsby fundus dystrophy. Am. J. Ophthalmol. 2008, 146:228-234.
193. Skerka C., et al. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol. Immunol. 2007, 44:3398-3406.
194. Smailhodzic D., et al. Central areolar choroidal dystrophy (CACD) and age-related macular degeneration (AMD): differentiating characteristics in multimodal imaging. Invest. Ophthalmol. Vis. Sci. 2011, 52:8908-8918.
195. Smailhodzic D., et al. Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. Ophthalmology 2012, 119:339-346.
196. Smailhodzic D., et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012, 119:2304-2311.
197. Small K.W. North Carolina macular dystrophy, revisited. Ophthalmology 1989, 96:1747-1754.
198. Small K.W. North Carolina macular dystrophy: clinical features, genealogy, and genetic linkage analysis. Trans. Am. Ophthalmol. Soc. 1998, 96:925-961.
199. Small K.W., et al. North Carolina's dominant progressive foveal dystrophy: how progressive is it?. Br. J. Ophthalmol. 1991, 75:401-406.
200. Smith W., et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001, 108:697-704.
201. Sobrin L., et al. Genetic profile for five common variants associated with age-related macular degeneration in densely affected families: a novel analytic approach. Eur. J. Hum. Genet. 2010, 18:496-501.
202. Souied E.H., et al. Optical coherent tomography features of malattia leventinese. Am. J. Ophthalmol. 2006, 141:404-407.
203. Spaide R.F., Curcio C.A. Drusen characterization with multimodal imaging. Retina 2010, 30:1441-1454.
204. Spaide R.F., et al. Characterization of peroxidized lipids in Bruch's membrane. Retina 1999, 19:141-147.
205. Stefko S.T., et al. Clinical spectrum of chromosome 6-linked autosomal dominant drusen and macular degeneration. Am. J. Ophthalmol. 2000, 130:203-208.
206. Stone E.M., et al. Missense variations in the fibulin 5 gene and age-related macular degeneration. N.Engl. J. Med. 2004, 351:346-353.
207. Stone E.M., et al. Asingle EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat. Genet. 1999, 22:199-202.
208. Sullivan K.M., et al. Fibulin-5 functions as an endogenous angiogenesis inhibitor. Lab. Invest. 2007, 87:818-827.
209. TAP Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch. Ophthalmol. 1999, 117:1329-1345.
210. Temel R.E., et al. ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins. J.Lipid. Res. 2007, 48:1618-1627.
211. Thornton J., et al. Smoking and age-related macular degeneration: a review of association. Eye (Lond.) 2005, 19:935-944.
212. Troutbeck R., et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin. Experiment. Ophthalmol. 2012, 40:18-26.
213. Ulbig M.R., et al. Membranoproliferative glomerulonephritis type II associated with central serous retinopathy. Am. J. Ophthalmol. 1993, 116:410-413.
214. van de Ven J.P.H., et al. Clinical evaluation of 3 families with basal laminar drusen caused by novel mutations in the complement factor H gene. Arch. Ophthalmol. 2012, 130:1038-1047.
215. van de Ven J.P.H., et al. Short-term changes of Basal laminar drusen on spectral-domain optical coherence tomography. Am. J. Ophthalmol. 2012, 154:560-567.
216. van de Ven J.P.H., et al. Afunctional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat. Genet. 2013, 45:813-817.
217. van de Ven J.P.H., et al. Association analysis of genetic and environmental risk factors in the cuticular drusen subtype of age-related macular degeneration. Mol. Vis. 2012, 18:2271-2278.
218. van der Schaft T.L., et al. Basal laminar deposit in the aging peripheral human retina. Graefes. Arch. Clin. Exp. Ophthalmol. 1993, 231:470-475.
219. van der Schaft T.L., et al. Histologic features of the early stages of age-related macular degeneration. A statistical analysis. Ophthalmology 1992, 99:278-286.
220. van Leeuwen R., et al. Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film?. Ophthalmology 2003, 110:1540-1544.
221. van Leeuwen R., et al. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch. Ophthalmol. 2003, 121:519-526.
222. Voo I., et al. North Carolina macular dystrophy: clinicopathologic correlation. Am. J. Ophthalmol. 2001, 132:933-935.
223. Walker P.D., et al. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod. Pathol. 2007, 20:605-616.
224. Walport M.J. Complement. First of two parts. N.Engl. J. Med. 2001, 344:1058-1066.
225. Walport M.J. Complement. Second of two parts. N.Engl. J. Med. 2001, 344:1140-1144.
226. Wang J., et al. Altered function of factor I caused by amyloid beta: implication for pathogenesis of age-related macular degeneration from Drusen. J.Immunol. 2008, 181:712-720.
227. Wang J.J., et al. Ten-year incidence and progression of age-related maculopathy: the blue Mountains Eye Study. Ophthalmology 2007, 114:92-98.
228. Wang L., et al. Abundant lipid and protein components of drusen. PLoS One 2010, 5:e10329.
229. Weber B.H., et al. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat. Genet. 1994, 8:352-356.
230. Weismann D., et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478:76-81.
231. Westeneng-van Haaften S.C., et al. Clinical and genetic characteristics of late-onset Stargardt's disease. Ophthalmology 2012, 119:1199-1210.
232. Westra D., et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol. Dial. Transplant. 2010, 25:2195-2202.
233. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 1995, 15:551-561.
234. Wimmers S., et al. Ion channels in the RPE. Prog. Retin. Eye. Res. 2007, 26:263-301.
235. Yannuzzi L.A., et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001, 21:416-434.
236. Yannuzzi L.A., et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990, 10:1-8.
237. Yates J.R., et al. Complement C3 variant and the risk of age-related macular degeneration. N.Engl. J. Med. 2007, 357:553-561.
238. Ying G.S., et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013, 120:122-129.
239. Yu Y., et al. Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. Hum. Mol. Genet. 2011, 20:3699-3709.
240. Zipfel P.F., et al. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol. Immunol. 2006, 43:97-106.
241. Zweifel S.A., et al. Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology 2010, 117:303-312 e301.